No clear cardio benefits were observed in a trial on nearly 15,000 male physicians taking multivitamin or placebo.
New analysis is available from the Physicians’ Health Study (PHS) II, a “gold standard” trial on nearly 15,000 male U.S. physicians taking multivitamin or placebo for over 10 years. This time, findings relate to multivitamin use and heart health.
Writing in the Journal of the American Medical Association (JAMA), researchers from Harvard Medical School and the Brigham and Women’s Hospital in Boston determined that “taking a daily multivitamin did not reduce major cardiovascular events,” including heart attack, stroke, and death by heart disease. Per 1000 person-years, multivitamin users experienced one slightly reduced risks of each condition compared to placebo.
“We’re not surprised by these results, but they don’t discount the many other benefits that multivitamins provide, including filling nutrient gaps, helping prevent neural tube birth defects, and serving in combination with other healthy habits as a basic and affordable insurance policy for overall wellness,” said Duffy MacKay, ND, vice president of scientific and regulatory affairs at CRN. “Even though two weeks ago this same study demonstrated a modest but significant reduction in total cancer risk in this same population, no one should expect the multivitamin to wipe out all diseases known to man.”
The Physicians’ Health Study II was supported by National Institutes of Health grants.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.